Azitra (AZTR) Depreciation & Amortization (CF) (2022 - 2026)
Azitra (AZTR) posted Depreciation & Amortization (CF) of $37692.0 for Q1 2026, up 7.66% on a QoQ basis from $35010.0 in Q4 2025, and up 10.68% year-over-year from $34055.0 in Q1 2025.
Azitra (AZTR) Depreciation & Amortization (CF) (2022 - 2026) Analysis & Trends
Azitra's Depreciation & Amortization (CF) history runs 5 years deep, the most recent figure standing at $37692.0 for Q1 2026.
- Quarterly Depreciation & Amortization (CF) rose 10.68% year-over-year to $37692.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $141706.0 (up 6.71% YoY) and the FY2025 annual result came in at $138069.0, up 5.25% from the prior year.
- Depreciation & Amortization (CF) was $37692.0 for Q1 2026 at Azitra, up from $35010.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $37692.0 in Q1 2026 and bottomed at $30148.0 in Q2 2022.
- A 5-year average of $33201.1 and a median of $32620.5 in 2023 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2024 — Depreciation & Amortization (CF) fell 0.46% — and 2026, when it grew 10.68%.
- Azitra's Depreciation & Amortization (CF) stood at $32370.0 in 2022, then fell by 0.33% to $32263.0 in 2023, then climbed by 3.02% to $33238.0 in 2024, then gained by 5.33% to $35010.0 in 2025, then advanced by 7.66% to $37692.0 in 2026.
- Business Quant data shows AZTR's Depreciation & Amortization (CF) at $37692.0 in Q1 2026, $35010.0 in Q4 2025, and $34766.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Nanobiotix | 1,792.52 Bn | 1,792.46 Bn | - | - |
| 2 | Akari Therapeutics | 999.95 Bn | 999.95 Bn | - | - |
| 3 | BeOne Medicines | 475.97 Bn | 471.17 Bn | 1.35 Bn | 41.14 Mn |
| 4 | Vertex Pharmaceuticals | 124.91 Bn | 117.66 Bn | 2.59 Bn | 55.90 Mn |
| 5 | Regeneron Pharmaceuticals | 72.31 Bn | 63.56 Bn | 3.31 Bn | 123.20 Mn |
| 6 | Belite Bio | 62.01 Bn | 62.01 Bn | - | - |
| 7 | Argenx Se | 54.23 Bn | 49.04 Bn | 1.41 Bn | - |
| 8 | Alnylam Pharmaceuticals | 38.31 Bn | 35.30 Bn | 959.66 Mn | - |
| 9 | Revolution Medicines | 36.16 Bn | 36.16 Bn | - | 2.20 Mn |
| 10 | Azitra | 2.05 Mn | 2.05 Mn | - | 37,692.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 37,692.00 |
| Mar 31, 2026 | 37,692.00 |
| Dec 31, 2025 | 35,010.00 |
| Dec 31, 2025 | 35,010.00 |
| Sep 30, 2025 | 34,766.00 |
| Sep 30, 2025 | 34,766.00 |
| Jun 30, 2025 | 34,238.00 |
| Jun 30, 2025 | 34,238.00 |
| Mar 31, 2025 | 34,055.00 |
| Mar 31, 2025 | 34,055.00 |
| Dec 31, 2024 | 33,238.00 |
| Dec 31, 2024 | 33,238.00 |
| Sep 30, 2024 | 32,997.00 |
| Sep 30, 2024 | 32,997.00 |
| Jun 30, 2024 | 32,507.00 |
| Jun 30, 2024 | 32,507.00 |
| Mar 31, 2024 | 32,446.00 |
| Mar 31, 2024 | 32,446.00 |
| Dec 31, 2023 | 32,263.00 |
| Dec 31, 2023 | 32,263.00 |